As a food, shiitake eaten daily for a month sharpens several immune-cell responses and lowers a common inflammation marker; sun-exposure makes it a genuine vitamin D source. These effects are real but small. Raw or undercooked mushrooms cause a distinctive rash that thorough cooking prevents; concentrated powders upset the stomach in a meaningful minority. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Absolute eosinophil count | Below 350 cells/mm³ | The dose-limiting response to concentrated shiitake |
| High-sensitivity C-reactive protein | Below 1.0 mg/L | The inflammation marker that fell in the shiitake feeding trial |
| Serum 25-hydroxyvitamin D | 40–60 ng/mL (100–150 nmol/L) | Confirms whether ultraviolet-treated shiitake contributes usable vitamin D |
| Triglycerides | Below 80 mg/dL | The one lipid fraction that moved in a shiitake trial |
| Alanine aminotransferase | Below 25 U/L in men, below 20 U/L in women | Rodent toxicology showed liver histology change at very high extract doses |
| Serum uric acid | 3.5–5.5 mg/dL | Purine load is the mechanistic basis for the speculative gout concern |
| Lymphocyte subsets and natural killer cell activity | No established target; track change from personal baseline | The mechanistic endpoint the trials actually moved |
| High-risk human papillomavirus DNA and RNA | Negative | The endpoint used in the mycelia extract clearance trial |
Cadence: Baseline panel before concentrated extracts. Complete blood count with differential and liver enzymes at 4–6 weeks, then 3 months, then every 6–12 months while use continues; 25-hydroxyvitamin D at 8–12 weeks; lipid panel at 3 months. A new rash or new abdominal symptoms warrant an immediate eosinophil count. Whole-mushroom culinary intake does not warrant a workup.